These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 11167825

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. CrkL functions as a nuclear adaptor and transcriptional activator in Bcr-Abl-expressing cells.
    Rhodes J, York RD, Tara D, Tajinda K, Druker BJ.
    Exp Hematol; 2000 Mar; 28(3):305-10. PubMed ID: 10720695
    [Abstract] [Full Text] [Related]

  • 3. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.
    Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW.
    Blood; 1994 Nov 01; 84(9):2912-8. PubMed ID: 7524758
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells.
    Salgia R, Uemura N, Okuda K, Li JL, Pisick E, Sattler M, de Jong R, Druker B, Heisterkamp N, Chen LB.
    J Biol Chem; 1995 Dec 08; 270(49):29145-50. PubMed ID: 7493940
    [Abstract] [Full Text] [Related]

  • 7. CRKL binding to BCR-ABL and BCR-ABL transformation.
    Kolibaba KS, Bhat A, Heaney C, Oda T, Druker BJ.
    Leuk Lymphoma; 1999 Mar 08; 33(1-2):119-26. PubMed ID: 10194128
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation.
    ten Bosch GJ, Kessler JH, Blom J, Joosten AM, Gambacorti-Passerini C, Melief CJ, Leeksma OC.
    Br J Haematol; 1998 Dec 08; 103(4):1109-15. PubMed ID: 9886328
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
    Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD.
    Oncogene; 1996 Feb 15; 12(4):839-46. PubMed ID: 8632906
    [Abstract] [Full Text] [Related]

  • 15. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.
    Uemura N, Salgia R, Li JL, Pisick E, Sattler M, Griffin JD.
    Leukemia; 1997 Mar 15; 11(3):376-85. PubMed ID: 9067577
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
    Carlesso N, Frank DA, Griffin JD.
    J Exp Med; 1996 Mar 01; 183(3):811-20. PubMed ID: 8642285
    [Abstract] [Full Text] [Related]

  • 19. Subcellular distribution of p210(BCR-ABL) in CML cell lines and primary CD34+ CML cells.
    Patel H, Marley SB, Greener L, Gordon MY.
    Leukemia; 2008 Mar 01; 22(3):559-71. PubMed ID: 18059481
    [Abstract] [Full Text] [Related]

  • 20. Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.
    Kardinal C, Konkol B, Schulz A, Posern G, Lin H, Adermann K, Eulitz M, Estrov Z, Talpaz M, Arlinghaus RB, Feller SM.
    FASEB J; 2000 Aug 01; 14(11):1529-38. PubMed ID: 10928987
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.